Literature DB >> 1563933

Candida laryngotracheitis: a complication of combined steroid and antibiotic usage in croup.

D M Burton1, A B Seid, D B Kearns, S M Pransky.   

Abstract

The use of corticosteroids to reduce the morbidity associated with laryngotracheobronchitis (croup) has been a controversial issue for many years. Recent literature, however, does support a decreased morbidity and increased clinical response when short-term steroids are used. As a prophylactic measure against bacterial superinfection, antibiotics are commonly utilized in the treatment of croup. We present the case of an otherwise healthy infant with severe croup who was hospitalized and treated with both steroids and antibiotics. A relapse in her symptoms led to the diagnosis of candida laryngotracheitis. We recommend close monitoring of patients with croup treated aggressively with steroids and antibiotics. Steroid use should be limited to 24 h with antibiotics reserved for patients with signs of bacterial infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1563933     DOI: 10.1016/0165-5876(92)90053-r

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  5 in total

1.  Role of steroids in treatment of croup.

Authors:  K Chugh
Journal:  Indian J Pediatr       Date:  2000-01       Impact factor: 1.967

Review 2.  Croup.

Authors:  David Johnson
Journal:  BMJ Clin Evid       Date:  2009-03-10

Review 3.  Tracheobronchial mycosis in a retrospective case-series study of five status asthmaticus patients.

Authors:  Garbo Mak; Paul C Porter; Venkata Bandi; Farrah Kheradmand; David B Corry
Journal:  Clin Immunol       Date:  2012-11-27       Impact factor: 3.969

4.  Scientific rationale for the use of alpha-adrenergic agonists and glucocorticoids in the therapy of pediatric stridor.

Authors:  Gustavo Nino; Orkun Baloglu; Maria J Gutierrez; Michael Schwartz
Journal:  Int J Otolaryngol       Date:  2011-12-19

Review 5.  Infraglottic and bronchial infections.

Authors:  A Uba
Journal:  Prim Care       Date:  1996-12       Impact factor: 2.907

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.